Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
University of Mississippi Medical Center
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02630394CT.gov A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Chest Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Azithromycin (this asset) | University of Mississippi Medical Center | P1 | CC · 43 |
| Tocilizumab | Assistance Publique - Hôpitaux de Paris | P3 | BB |
| Tinzaparin | Assistance Publique - Hôpitaux de Paris | P3 | B |
| Aspirin | Dr. med. Mahir Karakas | P3 | B |
| Atorvastatin | Dr. med. Mahir Karakas | P3 | B |
| Defibrotide | New York Medical College | P2 | B |
| a-001 | Anthera Pharmaceuticals | P2 | B |
| Unfractionated Heparin | Craig Seaman | P2 | CCC |
| Budesonide | Vanderbilt University | P1 | CC |
+2 more in the Acute Chest Syndrome cohort
Other indications for Azithromycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bronchiectasis | — | P4 | BBB · 73 |
| Cystic Fibrosis | — | P4 | BBB · 72 |
| Dry Eye Syndrome | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Azithromycin in Acute Chest Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/azithromycin-acute-chest-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →